Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of DA-302168S in Hepatic Impairment
NCT07877038Phase 1Not yet recruiting
- Sponsor
- Chengdu Diao Pharmaceutical Group
- Start
- Oct 2026
- Primary completion
- Apr 2027
01
Overview
Phase 1, open-label trial of DA-302168S in type 2 diabetes mellitus (T2DM), obesity and Overweight (3 arms), sponsored by Chengdu Diao Pharmaceutical Group. Primary endpoints: Peak Plasma Concentration and Area Under the Serum Concentration Curve From Time 0 to the Last Measurable Concentration. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
DA-302168S
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on NCT07877038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07877038.